The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
Chemical molecular‐based approach to overcome multidrug resistance in cancer by targeting P‐glycoprotein (P‐gp)
Abstract
Multidrug resistance (MDR) remains one of the major impediments for efficacious cancer chemotherapy. Increased efflux of multiple chemotherapeutic drugs by transmembrane ATP‐binding cassette (ABC) transporter superfamily is considered one of the primary causes for cancer MDR, in which the role of P‐glycoprotein (P‐gp/ABCB1) has been most well‐established. The clinical co‐administration of P‐gp drug efflux inhibitors, in combination with anticancer drugs which are P‐gp transport substrates, was considered to be a treatment modality to surmount MDR in anticancer therapy by blocking P‐gp‐mediated multidrug efflux. Extensive attempts have been carried out to screen for sets of nontoxic, selective, and efficacious P‐gp efflux inhibitors. In this review, we highlight the recent achievements in drug design, characterization, structure–activity relationship (SAR) studies, and mechanisms of action of the newly synthetic, potent small molecules P‐gp inhibitors in the past 5 years. The development of P‐gp inhibitors will increase our knowledge of the mechanisms and functions of P‐gp‐mediated drug efflux which will benefit drug discovery and clinical cancer therapeutics where P‐gp transporter overexpression has been implicated in MDR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Wang, Y., Patel, B. A., Anreddy, N., Zhang, Y., Zhang, G.-N., Alqahtani, S., Singh, S., Shukla, S., Kaddoumi, A., Ambudkar, S. V., et al. (2017) · Scientific Reports · doi:10.1038/srep42106 · Cited by 16
Self-citationRetractedCohen, A. J., Brauer, M., Burnett, R., Anderson, H. R., Frostad, J., Estep, K., Balakrishnan, K., Brunekreef, B., Dandona, L., Dandona, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30505-6 · Cited by 6,583
NF-κB, inflammation, immunity and cancer: coming of age
Taniguchi, K., & Karin, M. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.142 · Cited by 2,679
Wolber, G., & Langer, T. (2005) · Journal of Chemical Information and Modeling · doi:10.1021/ci049885e · Cited by 1,954
Chen, C.-J., Chin, J. E., Ueda, K., Clark, D. P., Pastan, I., Gottesman, M. M., & Roninson, I. B. (1986) · Cell · doi:10.1016/0092-8674(86)90595-7 · Cited by 1,898
Revisiting the role of ABC transporters in multidrug-resistant cancer
Robey, R. W., Pluchino, K. M., Hall, M. D., Fojo, A. T., Bates, S. E., & Gottesman, M. M. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0005-8 · Cited by 1,866
Farber, S., Diamond, L. K., Mercer, R. D., Sylvester, R. F., & Wolff, J. A. (1948) · New England Journal of Medicine · doi:10.1056/nejm194806032382301 · Cited by 1,806
Structure, Function, and Evolution of Bacterial ATP-Binding Cassette Systems
Davidson, A. L., Dassa, E., Orelle, C., & Chen, J. (2008) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00031-07 · Cited by 1,420
Twenty years on: the impact of fragments on drug discovery
Erlanson, D. A., Fesik, S. W., Hubbard, R. E., Jahnke, W., & Jhoti, H. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.109 · Cited by 1,000
Medicinal attributes of 1,2,3-triazoles: Current developments
Dheer, D., Singh, V., & Shankar, R. (2017) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2017.01.010 · Cited by 873
Multiple molecular mechanisms for multidrug resistance transporters
Higgins, C. F. (2007) · Nature · doi:10.1038/nature05630 · Cited by 860
Kathawala, R. J., Gupta, P., Ashby, C. R., & Chen, Z.-S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2014.11.002 · Cited by 777
Self-citationGOODMAN, L. S. (1946) · Journal of the American Medical Association · doi:10.1001/jama.1946.02870380008004 · Cited by 700
Reduced permeability in CHO cells as a mechanism of resistance to colchicine
Ling, V., & Thompson, L. H. (1974) · Journal of Cellular Physiology · doi:10.1002/jcp.1040830114 · Cited by 686
Li, W., Zhang, H., Assaraf, Y. G., Zhao, K., Xu, X., Xie, J., Yang, D.-H., & Chen, Z.-S. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.05.001 · Cited by 673
Self-citationABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development
Choi, Y., & Yu, A.-M. (2014) · Current Pharmaceutical Design · doi:10.2174/138161282005140214165212 · Cited by 629
P-glycoprotein Inhibition for Optimal Drug Delivery
Amin, M. L. (2013) · Drug Target Insights · doi:10.4137/dti.s12519 · Cited by 624
Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition
Zhou, S.-F. (2008) · Xenobiotica · doi:10.1080/00498250701867889 · Cited by 599
The ABC transporter structure and mechanism: perspectives on recent research
Jones, P. M., & George, A. M. (2004) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-003-3336-9 · Cited by 578
A systematic review on the clustering and co-occurrence of multiple risk behaviours
Meader, N., King, K., Moe-Byrne, T., Wright, K., Graham, H., Petticrew, M., Power, C., White, M., & Sowden, A. J. (2016) · BMC Public Health · doi:10.1186/s12889-016-3373-6 · Cited by 578
Bioactive Benzofuran derivatives: A review
Khanam, H., & Shamsuzzaman (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.11.039 · Cited by 554
The multi-factorial nature of clinical multidrug resistance in cancer
Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100645 · Cited by 528
Self-citationThe P-glycoprotein multidrug transporter
Sharom, F. J. (2011) · Essays in Biochemistry · doi:10.1042/bse0500161 · Cited by 509
Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Palmeira, A., Sousa, E., H. Vasconcelos, M., & M. Pinto, M. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712800167392 · Cited by 484
Lysosomes as mediators of drug resistance in cancer
Zhitomirsky, B., & Assaraf, Y. G. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2015.11.004 · Cited by 482
Self-citationStructural insight into substrate and inhibitor discrimination by human P-glycoprotein
Alam, A., Kowal, J., Broude, E., Roninson, I., & Locher, K. P. (2019) · Science · doi:10.1126/science.aav7102 · Cited by 469
Molecular structure of human P-glycoprotein in the ATP-bound, outward-facing conformation
Kim, Y., & Chen, J. (2018) · Science · doi:10.1126/science.aar7389 · Cited by 456
Genetic heterogeneity and cancer drug resistance
Turner, N. C., & Reis-Filho, J. S. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70335-7 · Cited by 454
Inhibition of the Multidrug Resistance P-Glycoprotein: Time for a Change of Strategy?
Callaghan, R., Luk, F., & Bebawy, M. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.056176 · Cited by 453
ABC transporters as mediators of drug resistance and contributors to cancer cell biology
Fletcher, J. I., Williams, R. T., Henderson, M. J., Norris, M. D., & Haber, M. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.03.001 · Cited by 423
Communication between Multiple Drug Binding Sites on P-glycoprotein
Martin, C., Berridge, G., Higgins, C. F., Mistry, P., Charlton, P., & Callaghan, R. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12429-7 · Cited by 418
Molecular mechanisms for tumour resistance to chemotherapy
Pan, S., Li, Z., He, Z., Qiu, J., & Zhou, S. (2016) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12581 · Cited by 401
Structural Basis of Substrate Recognition by the Multidrug Resistance Protein MRP1
Johnson, Z. L., & Chen, J. (2017) · Cell · doi:10.1016/j.cell.2017.01.041 · Cited by 375
Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor
Fox, E., & Bates, S. E. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.4.447 · Cited by 350
Molecular mechanisms of drug resistance and its reversal in cancer
Kartal-Yandim, M., Adan-Gokbulut, A., & Baran, Y. (2016) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2015.1015957 · Cited by 346
Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy
Silva, R., Vilas-Boas, V., Carmo, H., Dinis-Oliveira, R. J., Carvalho, F., de Lourdes Bastos, M., & Remião, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.013 · Cited by 339
Natural products as multidrug resistance modulators in cancer
Kumar, A., & Jaitak, V. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.027 · Cited by 334
Toward a Better Understanding of the Complexity of Cancer Drug Resistance
Gottesman, M. M., Lavi, O., Hall, M. D., & Gillet, J.-P. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103111 · Cited by 327
Structural basis of small-molecule inhibition of human multidrug transporter ABCG2
Jackson, S. M., Manolaridis, I., Kowal, J., Zechner, M., Taylor, N. M. I., Bause, M., Bauer, S., Bartholomaeus, R., Bernhardt, G., Koenig, B., et al. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0049-1 · Cited by 321
P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: A review
Abdallah, H. M., Al-Abd, A. M., El-Dine, R. S., & El-Halawany, A. M. (2015) · Journal of Advanced Research · doi:10.1016/j.jare.2014.11.008 · Cited by 319
Chemoresistance of glioblastoma cancer stem cells - much more complex than expected
Beier, D., Schulz, J. B., & Beier, C. P. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-128 · Cited by 312
Mechanism-based cancer therapy: resistance to therapy, therapy for resistance
Ramos, P., & Bentires-Alj, M. (2015) · Oncogene · doi:10.1038/onc.2014.314 · Cited by 272
Radadiya, A., & Shah, A. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.01.021 · Cited by 264
Designing Multiple Ligands – Medicinal Chemistry Strategies and Challenges
Morphy, R., & Rankovic, Z. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209787315594 · Cited by 262
Multidrug resistance: Physiological principles and nanomedical solutions
Kunjachan, S., Rychlik, B., Storm, G., Kiessling, F., & Lammers, T. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.018 · Cited by 259
Drug resistance: Still a daunting challenge to the successful treatment of AML
Shaffer, B. C., Gillet, J.-P., Patel, C., Baer, M. R., Bates, S. E., & Gottesman, M. M. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.02.001 · Cited by 259
Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update
Dong, J., Qin, Z., Zhang, W.-D., Cheng, G., Yehuda, A. G., Ashby, C. R., Chen, Z.-S., Cheng, X.-D., & Qin, J.-J. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100681 · Cited by 255
Self-citationZhang, L., Yan, K., Zhang, Y., Huang, R., Bian, J., Zheng, C., Sun, H., Chen, Z., Sun, N., An, R., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609370104 · Cited by 248
Self-citationA novel mitochondriotoxic small molecule that selectively inhibits tumor cell growth
Fantin, V. R., Berardi, M. J., Scorrano, L., Korsmeyer, S. J., & Leder, P. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00082-x · Cited by 228
ABC Transporter-Mediated Multidrug-Resistant Cancer
Amawi, H., Sim, H.-M., Tiwari, A. K., Ambudkar, S. V., & Shukla, S. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-13-7647-4_12 · Cited by 228
Integrating evolutionary dynamics into cancer therapy
Gatenby, R. A., & Brown, J. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0411-1 · Cited by 227
Zhitomirsky, B., & Assaraf, Y. G. (2015) · Oncotarget · doi:10.18632/oncotarget.2732 · Cited by 225
Self-citationOverview of P-glycoprotein inhibitors: a rational outlook
Srivalli, K. M. R., & Lakshmi, P. K. (2012) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s1984-82502012000300002 · Cited by 225
Amiri-Kordestani, L., Basseville, A., Kurdziel, K., Fojo, A. T., & Bates, S. E. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.02.002 · Cited by 219
Mohammad, I. S., He, W., & Yin, L. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.02.038 · Cited by 218
Combination of ligand- and structure-based methods in virtual screening
Drwal, M. N., & Griffith, R. (2013) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2013.02.002 · Cited by 209
Natural Products as Alternative Choices for P-Glycoprotein (P-gp) Inhibition
Dewanjee, S., Dua, T., Bhattacharjee, N., Das, A., Gangopadhyay, M., Khanra, R., Joardar, S., Riaz, M., Feo, V., & Zia-Ul-Haq, M. (2017) · Molecules · doi:10.3390/molecules22060871 · Cited by 209
Structure of a zosuquidar and UIC2-bound human-mouse chimeric ABCB1
Alam, A., Küng, R., Kowal, J., McLeod, R. A., Tremp, N., Broude, E. V., Roninson, I. B., Stahlberg, H., & Locher, K. P. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717044115 · Cited by 187
Molecular docking for virtual screening of natural product databases
Ma, D.-L., Chan, D. S.-H., & Leung, C.-H. (2011) · Chem. Sci. · doi:10.1039/c1sc00152c · Cited by 175
Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance
Shukla, S., Chen, Z.-S., & Ambudkar, S. V. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.005 · Cited by 168
Self-citationLysosomal accumulation of anticancer drugs triggers lysosomal exocytosis
Zhitomirsky, B., & Assaraf, Y. G. (2017) · Oncotarget · doi:10.18632/oncotarget.15155 · Cited by 163
Self-citationMolecular Basis of the Polyspecificity of P-Glycoprotein (ABCB1)
Chufán, E. E., Sim, H., & Ambudkar, S. V. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2014.10.003 · Cited by 147
Redundant angiogenic signaling and tumor drug resistance
Gacche, R. N., & Assaraf, Y. G. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.01.002 · Cited by 144
Self-citationBattle against Vancomycin-Resistant Bacteria: Recent Developments in Chemical Strategies
Dhanda, G., Sarkar, P., Samaddar, S., & Haldar, J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01093 · Cited by 121
Structure of the multidrug resistance P-glycoprotein
Higgins, C. F., Callaghan, R., Linton, K. J., et al. (1997) · Seminars in Cancer Biology · doi:10.1006/scbi.1997.0067 · Cited by 116
Fan, Y.-F., Zhang, W., Zeng, L., Lei, Z.-N., Cai, C.-Y., Gupta, P., Yang, D.-H., Cui, Q., Qin, Z.-D., Chen, Z.-S., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.021 · Cited by 116
Self-citationFragment Linking Strategies for Structure-Based Drug Design
Bancet, A., Raingeval, C., Lomberget, T., Borgne, M. L., Guichou, J., & Krimm, I. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00242 · Cited by 109
Hybrid Compounds as Multitarget Directed Anticancer Agents
Küçüksayan, E., & Özben, T. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616666160927155515 · Cited by 108
Cancer Stem Cells as a Potential Target to Overcome Multidrug Resistance
Cho, Y., & Kim, Y. K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00764 · Cited by 106
The translocation mechanism of P‐glycoprotein
Callaghan, R., Ford, R. C., & Kerr, I. D. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.11.083 · Cited by 102
Liu, X., Tee, H.-W., & Go, M. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.10.006 · Cited by 95
Dash, R. P., Babu, R. J., & Srinivas, N. R. (2017) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-017-0411-4 · Cited by 89
Cortes‐Dericks, L., Froment, L., Boesch, R., Schmid, R. A., & Karoubi, G. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-304 · Cited by 87
Developments in the Application of 1,2,3-Triazoles in Cancer Treatment
Slavova, K. I., Todorov, L. T., Belskaya, N. P., Palafox, M. A., & Kostova, I. P. (2020) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892815666200717164457 · Cited by 87
Wang, B., Ma, L., Wang, J., Lei, Z., Gupta, P., Zhao, Y., Li, Z., Liu, Y., Zhang, X., Li, Y., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00335 · Cited by 76
Self-citationFeng, S., Zhou, H., Wu, D., Zheng, D.-C., Qu, B., Liu, R., Zhang, C., Li, Z., Xie, Y., & Luo, H. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.07.007 · Cited by 72
Chan, K., Wong, I. L. K., Kan, J. W. Y., Yan, C. S. W., Chow, L. M. C., & Chan, T. H. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201121b · Cited by 71
Tariquidar Is an Inhibitor and Not a Substrate of Human and Mouse P-glycoprotein
Weidner, L. D., Fung, K.-L., Kannan, P., Moen, J. K., Kumar, J. S., Mulder, J., Innis, R. B., Gottesman, M. M., & Hall, M. D. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.067785 · Cited by 70
Inward- and outward-facing X-ray crystal structures of homodimeric P-glycoprotein CmABCB1
Kodan, A., Yamaguchi, T., Nakatsu, T., Matsuoka, K., Kimura, Y., Ueda, K., & Kato, H. (2019) · Nature Communications · doi:10.1038/s41467-018-08007-x · Cited by 69
Defying Multidrug Resistance! Modulation of Related Transporters by Flavonoids and Flavonolignans
Chambers, C. S., Viktorová, J., Řehořová, K., Biedermann, D., Turková, L., Macek, T., Křen, V., & Valentová, K. (2019) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.9b00694 · Cited by 69
de Klerk, D. J., Honeywell, R. J., Jansen, G., & Peters, G. J. (2018) · Cancers · doi:10.3390/cancers10120503 · Cited by 64
Singh, S., Prasad, N. R., Chufán, E. E., Patel, B. A., Wang, Y., Chen, Z., Ambudkar, S. V., & Talele, T. T. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401966m · Cited by 61
Self-citationStructure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing
Wu, K., Zhong, H., Li, G., Liu, C., Wang, H., Ma, D., & Leung, C. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.11.101 · Cited by 59
Sauna, Z. E., Andrus, M. B., Turner, T. M., & Ambudkar, S. V. (2004) · Biochemistry · doi:10.1021/bi035965k · Cited by 56
Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives
Li, X., Wang, L., Lei, Y., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.06.049 · Cited by 55
Wang, B., Zhao, B., Chen, Z., Pang, L.-P., Zhao, Y., Guo, Q., Zhang, X., Liu, Y., Hao-Zhang, Hao-Zhang, et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.041 · Cited by 53
Self-citationWu, X., Ma, J., Ye, Y., & Lin, G. (2015) · Journal of Chromatography B · doi:10.1016/j.jchromb.2015.11.024 · Cited by 52
Wong, I. L. K., Wang, B.-C., Yuan, J., Duan, L.-X., Liu, Z., Liu, T., Li, X., Hu, X., Zhang, X., Jiang, T., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00085 · Cited by 50
Qiu, Q., Liu, B., Cui, J. H., Li, Z., Deng, X., Qiang, H., Li, J., Liao, C., Zhang, B., Shi, W., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01787 · Cited by 49
Ranjbar, S., Khonkarn, R., Moréno, A., Baubichon-Cortay, H., Miri, R., Khoshneviszadeh, M., Saso, L., Edraki, N., Falson, P., & Firuzi, O. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.10.025 · Cited by 48
Yin, H., Dong, J., Cai, Y., Shi, X., Wang, H., Liu, G., Tang, Y., Liu, J., & Ma, L. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.053 · Cited by 44
Gu, X., Ren, Z., Tang, X., Peng, H., Yuan-fang Ma, A., Lai, Y., Peng, S., & Zhang, Y. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.02.050 · Cited by 40
Shahraki, O., Zargari, F., Edraki, N., Khoshneviszadeh, M., Firuzi, O., & Miri, R. (2016) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2016.1268976 · Cited by 40
Qiu, Q., Shi, W., Li, Z., Zhang, B., Pan, M., Cui, J. H., Dai, Y., Huang, W., & Qian, H. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01879 · Cited by 39
Bharate, J. B., Singh, S., Wani, A., Sharma, S., Joshi, P., Khan, I. A., Kumar, A., Vishwakarma, R. A., & Bharate, S. B. (2015) · Organic & Biomolecular Chemistry · doi:10.1039/c5ob00246j · Cited by 35
Riganti, C., Contino, M., Guglielmo, S., Perrone, M. G., Salaroglio, I. C., Milosevic, V., Giampietro, R., Leonetti, F., Rolando, B., Lazzarato, L., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01655 · Cited by 33
Cui, Q., Cai, C., Wang, J., Zhang, S., Gupta, P., Ji, N., Yang, Y., Dong, X.-D., Yang, D., & Chen, Z. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174095 · Cited by 32
Self-citationDei, S., Braconi, L., Trezza, A., Menicatti, M., Contino, M., Coronnello, M., Chiaramonte, N., Manetti, D., Perrone, M. G., Romanelli, M. N., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.03.054 · Cited by 29
Mudududdla, R., Guru, S. K., Wani, A., Sharma, S., Joshi, P., Vishwakarma, R. A., Kumar, A., Bhushan, S., & Bharate, S. B. (2015) · Organic & Biomolecular Chemistry · doi:10.1039/c5ob00233h · Cited by 28
Chen, C., Liu, N.-Y., Lin, H., Lee, C.-Y., Hung, C., & Chang, C. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.03.070 · Cited by 28
Kairuki, M., Qiu, Q., Pan, M., et al. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.06.013 · Cited by 27
Zhou, Y., He, P., Liu, A., Zhang, L., Liu, Y., & Dai, R. (2011) · Phytotherapy Research · doi:10.1002/ptr.3621 · Cited by 26
Bisi, A., Gobbi, S., Merolle, L., Farruggia, G., Belluti, F., Rampa, A., Molnar, J. A., Malucelli, E., & Cappadone, C. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.01.004 · Cited by 25
Nevskaya, A. A., Matveeva, M. D., Borisova, T. N., Niso, M., Colabufo, N. A., Boccarelli, A., Purgatorio, R., de Candia, M., Cellamare, S., Voskressensky, L. G., et al. (2018) · ChemMedChem · doi:10.1002/cmdc.201800177 · Cited by 25
Abcc10 status affects mammary tumour growth, metastasis, and docetaxel treatment response
Domanitskaya, N., Wangari‐Talbot, J., Jacobs, J. D., Peiffer, E., Mahdaviyeh, Y., Paulose, C., Malofeeva, E. V., Foster, K., Cai, K. Q., Zhou, Y., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.326 · Cited by 23
Ranjbar, S., Firuzi, O., Edraki, N., Shahraki, O., Saso, L., Khoshneviszadeh, M., & Miri, R. (2017) · MedChemComm · doi:10.1039/c7md00178a · Cited by 23
Sachs, J., Döhl, K., Weber, A., Bonus, M., Ehlers, F., Fleischer, E., Klinger, A., Gohlke, H., Pietruszka, J., Schmitt, L., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00400 · Cited by 22
Xanthone analogues as potent modulators of intestinal P-glycoprotein
Chae, S. W., Woo, S., Park, J. H., Kwon, Y., Na, Y., & Lee, H. J. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.01.006 · Cited by 21
Schwarz, T., Montanari, F., Cseke, A., Wlcek, K., Visvader, L., Palme, S., Chiba, P., Kuchler, K., Urban, E., & Ecker, G. F. (2016) · ChemMedChem · doi:10.1002/cmdc.201500592 · Cited by 20
Rullo, M., Niso, M., Pisani, L., Carrieri, A., Colabufo, N. A., Cellamare, S., & Altomare, C. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.10.043 · Cited by 18
Teodori, E., Dei, S., Coronnello, M., Floriddia, E., Bartolucci, G., Manetti, D., Romanelli, M. N., Porqueras, D. S. D., & Salerno, M. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.01.019 · Cited by 14
Pati, M. L., Abate, C., Contino, M., Ferorelli, S., Luisi, R., Carroccia, L., Niso, M., & Berardi, F. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.11.001 · Cited by 13
Qiu, Q., Shi, W., Zhao, S.-Y., Zhu, Y., Ding, Z., Zhou, S., Kairuki, M., Huang, W., & Qian, H. (2019) · Archiv der Pharmazie · doi:10.1002/ardp.201900127 · Cited by 13
Nasim, F., Schmid, D., Szakács, G., Sohail, A., Sitte, H. H., Chiba, P., & Stockner, T. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.572 · Cited by 13
Design and Synthesis of New Selective P-gp Substrates and Inhibitors
Cantore, M., Leopoldo, M., Berardi, F., Perrone, R., & Colabufo, N. A. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160810114008 · Cited by 11
Synthesis and biological evaluation of JL-A7 derivatives as potent ABCB1 inhibitors
Pan, M., Cui, J. H., Jiao, L., Ghaleb, H., Liao, C., Zhou, J., Kairuki, M., Lin, H., Huang, W., & Qian, H. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.06.015 · Cited by 11
Liu, T., Peng, Y., Li, X., Liu, L., Liu, F., & He, L. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.08.003 · Cited by 8
Research works printed but not linked: 47
- Seton‐Rogers S, 2016, Resistance: following different paths, Nat Rev Cancer, 16, 128, 10.1038/nrc.2016.23 · doi:10.1038/nrc.2016.23
- 10.1016/j.drup.2012.03.001 · doi:10.1016/j.drup.2012.03.001
- 10.1002/wcms.1316 · doi:10.1002/wcms.1316
- 10.1124/mol.58.3.624 · doi:10.1124/mol.58.3.624 · Paper page
- 10.1016/j.lfs.2018.10.048 · doi:10.1016/j.lfs.2018.10.048
- 10.2174/1381612822666160804093852 · doi:10.2174/1381612822666160804093852
- 10.1016/j.ejmech.2014.10.082 · doi:10.1016/j.ejmech.2014.10.082
- 10.1002/cmdc.201500538 · doi:10.1002/cmdc.201500538
- 10.1021/acs.jmedchem.6b00252 · doi:10.1021/acs.jmedchem.6b00252
- 10.1016/j.bmc.2016.04.055 · doi:10.1016/j.bmc.2016.04.055
- 10.1002/cmdc.201402463 · doi:10.1002/cmdc.201402463
- 10.1139/cjpp-2016-0518 · doi:10.1139/cjpp-2016-0518
- 10.1016/j.bmc.2016.03.065 · doi:10.1016/j.bmc.2016.03.065
- 10.1039/C6RA02405J · doi:10.1039/c6ra02405j
- 10.1016/j.bmc.2018.03.045 · doi:10.1016/j.bmc.2018.03.045
- 10.1111/cbdd.13338 · doi:10.1111/cbdd.13338
- 10.1016/j.bioorg.2019.01.039 · doi:10.1016/j.bioorg.2019.01.039
- 10.1021/jacs.6b11188 · doi:10.1021/jacs.6b11188
- 10.1021/acs.joc.8b00322 · doi:10.1021/acs.joc.8b00322
- 10.1021/acs.jmedchem.0c00337 · doi:10.1021/acs.jmedchem.0c00337
- 10.1016/j.ejmech.2018.04.012 · doi:10.1016/j.ejmech.2018.04.012
- 10.1080/14756366.2020.1747449 · doi:10.1080/14756366.2020.1747449
- 10.1016/j.ejmech.2018.01.092 · doi:10.1016/j.ejmech.2018.01.092
- 10.1021/jm9810194 · doi:10.1021/jm9810194
- 10.1021/jm050542x · doi:10.1021/jm050542x
- 10.1021/jm0614432 · doi:10.1021/jm0614432
- 10.1002/cmdc.201500143 · doi:10.1002/cmdc.201500143
- 10.1021/jm400930e · doi:10.1021/jm400930e
- 10.1016/j.bmc.2015.07.027 · doi:10.1016/j.bmc.2015.07.027
- 10.1016/j.ejmech.2016.09.070 · doi:10.1016/j.ejmech.2016.09.070
- Feng S‐L, 2020, Nobiletin potentiates paclitaxel anticancer efficacy in A549/T xenograft model: pharmacokinetic and pharmacological study, Phytomedicine, 67
- 10.1515/hc-2016-0034 · doi:10.1515/hc-2016-0034
- 10.1016/j.ejphar.2014.10.058 · doi:10.1016/j.ejphar.2014.10.058
- 10.1039/C4MD00506F · doi:10.1039/c4md00506f
- 10.1016/j.bmcl.2015.05.018 · doi:10.1016/j.bmcl.2015.05.018
- 10.1016/j.bmc.2015.05.016 · doi:10.1016/j.bmc.2015.05.016
- 10.1021/mp500770e · doi:10.1021/mp500770e
- 10.1016/j.ejmech.2016.08.044 · doi:10.1016/j.ejmech.2016.08.044
- 10.1016/j.ejmech.2014.10.044 · doi:10.1016/j.ejmech.2014.10.044
- 10.1021/acs.joc.7b02012 · doi:10.1021/acs.joc.7b02012
- 10.1016/j.ejmech.2018.01.019 · doi:10.1016/j.ejmech.2018.01.019
- 10.1039/C5RA19857G · doi:10.1039/c5ra19857g
- 10.1016/j.ymeth.2014.12.012 · doi:10.1016/j.ymeth.2014.12.012
- 10.3390/molecules24091661 · doi:10.3390/molecules24091661
- 10.1016/j.ejmech.2016.01.034 · doi:10.1016/j.ejmech.2016.01.034
- 10.1016/j.ijpharm.2016.02.022 · doi:10.1016/j.ijpharm.2016.02.022
- 10.1016/j.ijantimicag.2014.10.023 · doi:10.1016/j.ijantimicag.2014.10.023
Cited by
Therapeutic strategies to overcome taxane resistance in cancer
Das, T., Anand, U., Pandey, S. K., Ashby, C. R., Assaraf, Y. G., Chen, Z.-S., & Dey, A. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100754 · Cited by 253
Self-citationHanssen, K. M., Haber, M., & Fletcher, J. I. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100795 · Cited by 102
The role of FOXP3 in non-small cell lung cancer and its therapeutic potentials
Peng, J., Yang, S., Ng, C. S. H., & Chen, G. G. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108333 · Cited by 21
Ji, Q.-L., Zeng, Y., Zhou, H., Wang, Q.-B., Zhou, R.-Y., Zhang, J.-J., & Wang, X. (2026) · Scientific reports · doi:10.1038/s41598-026-49617-6 · Cited by 1
“P-glycoprotein (P-gp) is a typical membrane-associated pump that actively transports drugs out of cells 15 .”
Metadata
- Authors
- Zhang, H., Xu, H., Ashby, C. R., Assaraf, Y. G., Chen, Z., & Liu, H.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2020-10-12
- Volume
- 41
- Issue
- 1
- Pages
- 525-555
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W3091980736
- Cited by
- 270
- References
- 117
- FWCI
- 11.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.